Merck reports positive results from phase 3 KEYNOTE-859 trial of Keytruda in combo with chemotherapy to treat HER2-negative gastric or GEJ adenocarcinoma

Merck, known as MSD outside of the United States and Canada, announced positive topline results from the pivotal phase 3 KEYNOTE-859 trial investigating Keytruda, Merck